Results 271 to 280 of about 172,155 (289)

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Lancet, The, 2019
Beyong Duk Ye, Adi Lahat, Sigal Fishman
exaly  

Detailed analysis of the latencies of median nerve somatosensory evoked potential components, 2: analysis of subcomponents of the P13/14 and N20 potentials

Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1997
Masahiro Sonoo
exaly  

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

Modern Rheumatology, 2015
Tsutomu Takeuchi, Hisashi Yamanaka, Yoshiya Tanaka   +2 more
exaly  

P13– Adapting ADAPTE

Otolaryngology–Head and Neck Surgery, 2010
Orit Schieir, Glen Hazlewood, Pooneh Akhavan, Vivian Bykerk, Claire Bombardier   +4 more
openaire   +1 more source

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab

Modern Rheumatology, 2017
Yoshiya Tanaka, Hisashi Yamanaka, Tsutomu Takeuchi   +2 more
exaly  

P13 - Ceramica invetriata

2016
STUDIO DELLA CERAMICA INVETRIATA DAL SANTUARIO DI NARCE (XVI-XIX SEC.D.C)
openaire   +3 more sources

Knockdown of the mitochondria‐localized protein p13 protects against experimental parkinsonism

EMBO Reports, 2018
Atsushi Kasai, Takanobu Nakazawa, Kazuya Ikeda   +2 more
exaly  

Statistical optimization of production and tannery applications of a keratinolytic serine protease from Bacillus subtilis P13

Process Biochemistry, 2011
G Archana
exaly  

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease

Inflammatory Bowel Diseases, 2018
Gionata Fiorino, Daniela Gilardi, Federica Furfaro   +2 more
exaly  

Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes

Digestive Diseases and Sciences, 2018
Nikolas Plevris, Philip Jenkinson, Mathew Lyons   +2 more
exaly